Officinae Bio

What Officinae Bio does

Officinae Bio is a Venice, Italy-based biotechnology company that provides an AI-driven mRNA design and synthesis platform serving biotechnology and pharmaceutical developers of mRNA-based therapeutics, including protein replacement therapies, gene editing programs, and cancer immunotherapies. The company is registered as Officinae Bio Srl, was founded in 2023 (per company-history event timeline), and operates from a registered headquarters on the Isola della Giudecca in Venice, a mailing address in Mestre-Venezia, and a DNA foundry manufacturing facility in Roncade (Treviso) located within the Future Farming Science Hub.

The company's core technology is the Mercurius AI platform, which integrates public and proprietary biological data into a knowledge graph enriched by Bayesian networks to model complex dependencies and uncertainties across biological variables. Mercurius computes conditional probabilities over different sequence-design choices, optimizing 5' and 3' UTRs, polyA tails, capping strategies, and chemical modifications for application-specific, tissue-aware mRNA expression. Internal evidence cited on the company site includes higher protein expression versus commercial benchmarks in cell-based assays and higher lung-to-spleen expression ratios in BALB/c mice for OB-engineered constructs. Layered on top of the engine is the Breeze BioCAD web application (customer.officinae.bio), a modular design environment with templates including pSEVA, AAV, TAR, t-DNA, and linear DNA for mRNA IVT, augmented by a Composer Tool for bulk design and a Sequence Doctor module that validates constructs for manufacture readiness before order submission.

Officinae Bio monetizes through three phase-appropriate service bundles — RNAExpress (from €485, single transfection-ready mRNA, 15 business days), HITSmart (from €5,000, six mRNAs plus GFP control at pre-clinical grade, 21 business days), and LEADvantage (from €15,000, three mRNAs plus Luc control with organ-specific optimization, 31 business days) — complemented by modular DNA synthesis, custom cloning, and biomodule fees (€89 per biomodule at synthesis time). Distribution combines self-serve platform transactions with an enterprise Calendly route to commercial staff (Maria Vittoria Ortenzi). In November 2024, Maravai LifeSciences announced its acquisition of Officinae Bio's DNA and RNA business, integrating the company into the Maravai ecosystem alongside TriLink BioTechnologies (CleanCap reagents), Cygnus Technologies (impurity analytics), Alphazyme (ISO 13485 enzymes), and Glen Research (oligo synthesis), thereby extending the offering from design and discovery through GMP manufacturing.

Name

Officinae Bio

Legal name

Officinae Bio Srl

Website

https://officinae.bio

Company type

Private

Founded year

2023

Operating status

Operating

Headcount range

11–50 employees

Short description

Officinae Bio is a Venice-based biotechnology company providing AI-powered mRNA sequence design and custom synthesis services to biopharmaceutical developers via the Mercurius AI platform, Breeze BioCAD design environment, and tiered discovery-to-preclinical service bundles, operating as part of the Maravai LifeSciences ecosystem.

Ownership category

akta.pro rank

Product category

AI-Powered mRNA Design & Synthesis Platform

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836), Services-Prepackaged Software (7372)

akta.pro primary industry

RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics) (HLAAADAG)

akta.pro secondary industries

Library & Diversity Generation Platforms (display libraries, DNA-encoded libraries for biologics, variant libraries) (HLAAAIAL), Bioinformatics & Multi-omics Analysis Software (HLAGAJAD), mRNA Therapeutics (vaccines, protein replacement, immuno-oncology) (HLAAADAA)

Keywords

• MRNA design platform
• AI sequence optimization
• Custom DNA synthesis
• Biotechnology services
• Synthetic biology software

Headquarters

HQ city

Venice

HQ country

Italy

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales

Revenue model

1. Custom mRNA Synthesis and Design Services: Customers provide a gene of interest and receive custom mRNA constructs optimized via the Mercurius AI platform. Service tiers (RNAExpress, HITSmart, LEADvantage) deliver 1-6+ custom mRNAs with varying turnaround times and purity grades (transfection-ready to pre-clinical grade). Revenue is generated per project/service bundle on a one-time basis.
2. DNA Synthesis and Gene Cloning Services: DNA synthesis, custom cloning, and gene synthesis services through the Breeze BioCAD platform. Customers can upload sequences, design constructs using modular biomodules, and order synthesis with additional services (volume amplification, purification, delivery). Part reuse from previous orders reduces synthesis costs.
3. Biomodule Synthesis Fees: Public biomodules can be designed and used at no cost for R&D; a nominal fee of 89 EUR per biomodule is charged when used for synthesis. Private biomodules can be created at no cost but incur the 89 EUR synthesis fee when ordered.

Pricing tiers

Go-to-market motion2 records

Distribution channels2 records

Marketing channels3 records

Core offering

Officinae Bio provides an AI-powered biological design and manufacturing platform for mRNA engineering. Its core offering centers on the Mercurius AI engine, which uses Bayesian networks and a knowledge graph to optimize UTRs, polyA tails, capping strategies, and chemical modifications for tissue-specific mRNA expression. Customers access this through the Breeze BioCAD web-based design platform and three phase-appropriate service bundles—RNAExpress (discovery), HITSmart (cell-line tailored), and LEADvantage (organ-specific)—that deliver custom DNA and mRNA constructs at transfection-ready to pre-clinical grades.

Product overview

Officinae Bio offers a modular mRNA engineering platform centered on the Breeze BioCAD web application. The core product is the Mercurius AI platform, which uses Bayesian networks to optimize mRNA sequence design including UTRs, polyA tails, capping strategies, and chemical modifications. This AI engine powers three phase-appropriate service bundles: RNAExpress (standard codon optimization), HITSmart (cell line-tailored optimization), and LEADvantage (organ-specific optimization). The platform includes modular design tools (Breeze BioCAD, Composer Tool), validation tools (Sequence Doctor), and specialized templates for mRNA in vitro transcription. All services are offered as part of the Maravai LifeSciences ecosystem.

Differentiator

Problem solved

Functional benefit

Products and services

• Mercurius AI Platform AI-powered mRNA design engine that integrates public and proprietary data into a knowledge graph enriched by Bayesian networks, capturing complex biological dependencies to optimize UTRs, polyA tails, capping strategies, and chemical modifications for application-specific, tissue-aware mRNA expression. Used by biotech and pharma R&D teams developing mRNA therapeutics including protein replacement, gene editing, and cancer immunotherapy.
• Breeze BioCAD Self-serve web-based modular design system for DNA and mRNA construct engineering. Customers build constructs from biomodules, perform bulk design, validate sequences for manufacture, and submit synthesis orders directly through the platform. Targets biotech and pharma R&D teams needing modular construct design templates including pSEVA, AAV, TAR, t-DNA, genome editing, and linear DNA for RNA IVT.
• RNAExpress Discovery-phase service bundle providing standard codon optimization for mammalian cells using universal UTRs from Hbb. Delivers 1 custom mRNA (50 µg) with custom gene IVT at transfection-ready purity within 15 business days, priced at 485 EUR all-inclusive launch offer. For biotech and pharma researchers needing rapid entry-level mRNA constructs.
• HITSmart Hit-to-lead service bundle providing cell line-tailored codon, UTR, and polyA optimization to boost expression and targeted activity. Delivers 6 custom mRNAs plus 1 control GFP mRNA (50 µg each) at pre-clinical grade purity within 21 business days, priced from 5,000 EUR. Customer provides gene of interest and cell line of choice.
• LEADvantage Lead-optimization service bundle providing organ-specific optimization of codon, UTR, cap, and chemical modifications to enhance expression, safety, and targeting. Delivers 3 custom mRNAs plus 1 control Luc mRNA (150 µg each) at pre-clinical grade purity within 31 business days, priced from 15,000 EUR. Customer provides gene of interest and target organ.
• Custom DNA Synthesis and Gene Cloning Standalone DNA synthesis, custom cloning, and gene synthesis services accessed through the Breeze BioCAD platform. Customers upload sequences, design constructs with modular biomodules, and order synthesis with add-on services (volume amplification, purification, form, delivery). Part reuse from prior orders reduces synthesis costs. Available globally through the Officinae Bio website.

Quantifiable outcome

• OB-engineered mRNAs show significantly higher protein expression than commercial benchmarks in cell-based assays
• +1 more outcomes

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature3 records

Partnerships

Six partnerships are on record, tiered supporting and core.

• Sartorius PolyplussupportingStrategic or Co-development Partner · 15 October 2025Sartorius Polyplus co-presented a webinar with Officinae Bio and TriLink BioTechnologies on October 15, 2025, focused on advancements in mRNA design and delivery. The webinar covered how AI, chemical modifications, and novel lipid-based reagents can improve mRNA effectiveness and biodistribution for therapeutic applications.
• Maravai LifeSciencescoreStrategic or Co-development Partner · 1 November 2024Maravai LifeSciences is the parent ecosystem of Officinae Bio. In November 2024, Maravai announced plans to acquire Officinae Bio's DNA and RNA business. As part of the Maravai ecosystem, Officinae Bio gains seamless access to GMP manufacturing and commercial production capabilities, leveraging clinically approved critical reagents from sister companies.
• TriLink BioTechnologiescoreTechnology or IntegrationTriLink BioTechnologies provides clinically approved mRNA reagents with CleanCap technology. As a partner within the Maravai LifeSciences ecosystem, TriLink's reagents are integrated into Officinae Bio's mRNA design and synthesis workflow, enabling customers to access GMP-grade mRNA reagents.
• Cygnus TechnologiessupportingTechnology or IntegrationCygnus Technologies provides gold-standard impurity detection from preclinical development to commercial release. Integrated within the Maravai ecosystem to ensure quality and purity validation across Officinae Bio's mRNA synthesis offerings.
• AlphazymesupportingTechnology or IntegrationAlphazyme is a trusted source of ISO 13485:2016-certified high-performance enzymes for mRNA manufacturing. As part of the Maravai ecosystem, Alphazyme's enzymes are available to Officinae Bio customers for use in mRNA production workflows.
• Glen ResearchsupportingTechnology or IntegrationGlen Research is the leading provider of reagents for DNA and RNA oligonucleotide synthesis and purification. Integrated into the Officinae Bio ecosystem to support DNA and RNA synthesis services.

Scale indicators2 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Inceptive: AI-focused mRNA design company using deep learning to engineer RNA therapeutics. Directly comparable to Officinae Bio's Mercurius platform in applying AI/ML to mRNA sequence optimization for therapeutic applications.
• Cradle Bio: AI platform for protein and biologics engineering, helping customers design improved biological sequences. Comparable in offering ML-driven design-as-a-service for therapeutic molecules with similar tiered service bundles.
• BigHat Biosciences: AI/ML-guided antibody design and engineering platform combining wet-lab and computational design. Comparable as a services-led AI-biology company serving biopharma with custom-engineered biological sequences.
• Generate Biomedicines: Generative AI platform for designing novel protein therapeutics across multiple modalities. Overlaps with Officinae Bio in applying foundation-model approaches to programmable biology for therapeutic development.
• Absci: AI-powered generative biology company combining wet-lab data with ML models for protein and antibody design. Comparable as a platform combining proprietary data, ML, and services revenue from biopharma customers.

Emerging players

• Atomic AI: AI-driven RNA structure prediction and design company. Adjacent to Officinae Bio's mRNA design focus with overlapping RNA-targeting AI/ML capabilities though at an earlier commercialization stage.

Broad incumbents

• TriLink BioTechnologies: Established mRNA reagent and CDMO provider (and Maravai sister company) supplying CleanCap and other mRNA manufacturing inputs. A broad incumbent operating in the same mRNA value chain that Officinae Bio addresses at the design stage.
• CureVac: Clinical-stage mRNA therapeutics company with proprietary RNA optimization expertise. Comparable as an established player with deep mRNA sequence-engineering know-how operating in the same therapeutic areas Officinae Bio serves.
• Aldevron (Danaher): Large-scale CDMO providing plasmid DNA, mRNA, and protein services for therapeutic developers (now part of Danaher). Overlaps with Officinae Bio's custom DNA and mRNA synthesis service offerings but at significantly greater scale.
• Ginkgo Bioworks: Synthetic biology platform offering cell engineering and organism design services via a foundry model. Comparable to Officinae Bio's biomodule/DNA foundry approach but at much broader scope (whole organisms vs. mRNA constructs).

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/officinae-bio

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Officinae Bio